Novel approaches to DLBCL-RS treatment with published results
| Treatment . | Number of patients . | Median number prior Rx (CLL + RT) . | ORR/CRR (%) . | Median PFS/DOR(mo) . | Median OS (mo) . |
|---|---|---|---|---|---|
| Small-molecule targeted agents . | . | . | . | . | . |
| Venetoclax monotherapy38 | 7 | NR | 43/0 | NR/NR | NR |
| Acalabrutinib monotherapy25 | 25 | 1 for RT | 40/8 | 3.2/6.2 | NR |
| DTRM-555 (novel BTKi DTRMWXHS- 12– everolimus–pomalidomide)39 | 24 | 5 | 45/9 | NR/NR | NR |
| Pirtobrutinib26 | 9 | 6 (including 100% treated with covalent BTKi) | 67/NR | NR/NR | NR |
| CIT + targeted agents | |||||
| R-EPOCH− venetoclax28 | 26 | 1 for CLL, 0 for RT | 62/50 | 10.1/NR | 19.6 |
| Checkpoint inhibitors | |||||
| Pembrolizumab30 | 9 | 5 | 44/0 | NR/NR | 10.1 |
| Pembrolizumab31 | 23 (2 with CHL) | 3 for RT, NR for CLL | 5/0 (excluding 2 responders with CHL) | 1.6/NR | 3.8 |
| Ibrutinib-nivolumab40 | 24 | 3 | 43/35 | NR/10. | 13.8 |
| Ibrutinib- nivolumab41 | 20 | 2 | 65/10 | 5.0/6.9 | 10.3 |
| Venetoclax-obinutuzumab- atezolizumab33 | 7 | NR | 100/71 | Not reached/not reached | NR |
| Bispecific antibodies | |||||
| Blinatumomab monotherapy (Leukemia, in press) | 9 | 4 for CLL +2 for DLBCL-RS | 22/11 | 1.9/NR | 10.3 |
| Blinatumomab after R-CHOP34 | 31 | 2 for CLL | 54/39 | NR/NR | NR |
| Antibody-drug conjugates | |||||
| Zilovertamab vedotin36 | 6 | NR | 67/17 | NR/NR | NR |
| CAR T | |||||
| CD19 CAR T42 | 6 (DLBCL only) | 5 | 67/67 | NR/NR | NR |
| Axicabtagene ciloleucel43 | 8 | 4 | 100/63 | NR/NR | NR |
| Lisocabtagene maraleucel (European Breyanzi label) | 4 | NR | 50/25 | NR/2 | NR |
| Treatment . | Number of patients . | Median number prior Rx (CLL + RT) . | ORR/CRR (%) . | Median PFS/DOR(mo) . | Median OS (mo) . |
|---|---|---|---|---|---|
| Small-molecule targeted agents . | . | . | . | . | . |
| Venetoclax monotherapy38 | 7 | NR | 43/0 | NR/NR | NR |
| Acalabrutinib monotherapy25 | 25 | 1 for RT | 40/8 | 3.2/6.2 | NR |
| DTRM-555 (novel BTKi DTRMWXHS- 12– everolimus–pomalidomide)39 | 24 | 5 | 45/9 | NR/NR | NR |
| Pirtobrutinib26 | 9 | 6 (including 100% treated with covalent BTKi) | 67/NR | NR/NR | NR |
| CIT + targeted agents | |||||
| R-EPOCH− venetoclax28 | 26 | 1 for CLL, 0 for RT | 62/50 | 10.1/NR | 19.6 |
| Checkpoint inhibitors | |||||
| Pembrolizumab30 | 9 | 5 | 44/0 | NR/NR | 10.1 |
| Pembrolizumab31 | 23 (2 with CHL) | 3 for RT, NR for CLL | 5/0 (excluding 2 responders with CHL) | 1.6/NR | 3.8 |
| Ibrutinib-nivolumab40 | 24 | 3 | 43/35 | NR/10. | 13.8 |
| Ibrutinib- nivolumab41 | 20 | 2 | 65/10 | 5.0/6.9 | 10.3 |
| Venetoclax-obinutuzumab- atezolizumab33 | 7 | NR | 100/71 | Not reached/not reached | NR |
| Bispecific antibodies | |||||
| Blinatumomab monotherapy (Leukemia, in press) | 9 | 4 for CLL +2 for DLBCL-RS | 22/11 | 1.9/NR | 10.3 |
| Blinatumomab after R-CHOP34 | 31 | 2 for CLL | 54/39 | NR/NR | NR |
| Antibody-drug conjugates | |||||
| Zilovertamab vedotin36 | 6 | NR | 67/17 | NR/NR | NR |
| CAR T | |||||
| CD19 CAR T42 | 6 (DLBCL only) | 5 | 67/67 | NR/NR | NR |
| Axicabtagene ciloleucel43 | 8 | 4 | 100/63 | NR/NR | NR |
| Lisocabtagene maraleucel (European Breyanzi label) | 4 | NR | 50/25 | NR/2 | NR |
NR, not reported; RT, Richter’s transformation.